Q-omics provides the consensus-scored BTF3P10 profile across patient tissues and cancer cell-line models. BTF3P10 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BTF3P10 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, BTF3P10 RNA expression shows 10,083 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where BTF3P10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3P10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3P10 survival associations across molecular data types. BTF3P10 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3P10 RNA expression–survival associations across cancer types. High BTF3P10 expression shows unfavorable associations in MESO, KICH and LIHC, but favorable associations in KIRC, BRCA and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BTF3P10 RNA expression.
This table summarizes BTF3P10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for BTF3P10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3P10 shows lower tumor expression in STAD and THCA and higher tumor expression in COAD, LUAD, KIRC and READ. The COAD box plot shows higher BTF3P10 RNA expression in tumor versus normal tissue (log2 FC = +0.641, t-test p < 0.001).
This table shows molecular features associated with BTF3P10 in patient tissues and cancer cell lines. In patient samples, BTF3P10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
